Literature DB >> 17975163

Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice.

Kira H Brämswig1, Regina Knittelfelder, Silke Gruber, Eva Untersmayr, Angelika B Riemer, Krisztina Szalai, Reinhard Horvat, Robert Kammerer, Wolfgang Zimmermann, Christoph C Zielinski, Otto Scheiner, Erika Jensen-Jarolim.   

Abstract

PURPOSE: The carcinoembryonic antigen (CEA) is a glycoprotein that is overexpressed in nearly 50% of all human and veterinarian tumors. At present, anti-CEA antibodies are being tested in clinical studies as passive immunotherapeutics. This study aims to establish an active immunotherapy for the poorly immunogenic CEA glycoprotein by generating antigen surrogates. EXPERIMENTAL
DESIGN: We used the monoclonal anti-CEA antibody Col-1 and the biopanning method to generate peptide mimics (mimotopes) of the Col-1 epitope. The peptide showing the highest specificity and mimicry was synthesized as an octameric multiple antigenic mimotope (MAM). Subsequently, immunogenicity of the selected mimotope was examined in BALB/c mice. We assessed antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity mediated by the induced antibodies on CEA-expressing HT29 tumor cells. Furthermore, after immunization, the BALB/c mice were transplanted s.c. with Meth-A/CEA tumor cells.
RESULTS: When BALB/c mice were immunized with this MAM, they generated a specific humoral immune response against CEA. The mimotope-induced polyclonal and poly-isotypic antibodies induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Furthermore, when MAM-immunized mice were transplanted s.c. with Meth-A/CEA cells expressing human CEA, a suppressed tumor growth was observed.
CONCLUSION: From our results, we can conclude that the Col-1 epitope of the glycoprotein CEA can be translated into an immunogenic peptide mimic. The mimotope-induced antibodies recognize CEA and do effectively inhibit growth of CEA-positive tumors. Based on these finding, we suggest that the generated mimotopes are candidates for active immunotherapy of CEA-expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975163     DOI: 10.1158/1078-0432.CCR-07-0692

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  AllergoOncology: the role of IgE-mediated allergy in cancer.

Authors:  E Jensen-Jarolim; G Achatz; M C Turner; S Karagiannis; F Legrand; M Capron; M L Penichet; J A Rodríguez; A G Siccardi; L Vangelista; A B Riemer; H Gould
Journal:  Allergy       Date:  2008-07-26       Impact factor: 13.146

2.  Cancer-associated CD43 glycoforms as target of immunotherapy.

Authors:  Franca Maria Tuccillo; Camillo Palmieri; Giuseppe Fiume; Annamaria de Laurentiis; Marco Schiavone; Cristina Falcone; Enrico Iaccino; Ricciarda Galandrini; Cristina Capuano; Angela Santoni; Francesco Paolo D'Armiento; Claudio Arra; Antonio Barbieri; Fabrizio Dal Piaz; David Venzon; Patrizia Bonelli; Franco Maria Buonaguro; Iris Scala; Massimo Mallardo; Ileana Quinto; Giuseppe Scala
Journal:  Mol Cancer Ther       Date:  2013-12-19       Impact factor: 6.261

Review 3.  Mimotope vaccination--from allergy to cancer.

Authors:  Regina Knittelfelder; Angelika B Riemer; Erika Jensen-Jarolim
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

Review 4.  Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis.

Authors:  Giuseppe Colloca; Antonella Venturino; Pasquale Vitucci
Journal:  Med Oncol       Date:  2017-09-07       Impact factor: 3.064

5.  A mimotope gene encoding the major IgE epitope of allergen Phl p 5 for epitope-specific immunization.

Authors:  J Wallmann; M Proell; T Stepanoska; B Hantusch; I Pali-Schöll; T Thalhamer; J Thalhamer; E Jensen-Jarolim; A Hartl
Journal:  Immunol Lett       Date:  2008-12-25       Impact factor: 3.685

Review 6.  The roles of mast cells in anticancer immunity.

Authors:  Dyana K Dalton; Randolph J Noelle
Journal:  Cancer Immunol Immunother       Date:  2012-04-18       Impact factor: 6.968

7.  Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies.

Authors:  Marlene Weichselbaumer; Michael Willmann; Martin Reifinger; Josef Singer; Erika Bajna; Yuriy Sobanov; Diana Mechtcherikova; Edgar Selzer; Johann G Thalhammer; Robert Kammerer; Erika Jensen-Jarolim
Journal:  PLoS Curr       Date:  2011-03-16

8.  Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity.

Authors:  Julia Latzka; Sonja Gaier; Gerlinde Hofstetter; Nina Balazs; Ursula Smole; Soldano Ferrone; Otto Scheiner; Heimo Breiteneder; Hubert Pehamberger; Stefan Wagner
Journal:  PLoS One       Date:  2011-05-06       Impact factor: 3.240

9.  Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.

Authors:  Panagiotis Karagiannis; Josef Singer; James Hunt; Samuel K E Gan; Sarah M Rudman; Diana Mechtcheriakova; Regina Knittelfelder; Tracy R Daniels; Philip S Hobson; Andrew J Beavil; James Spicer; Frank O Nestle; Manuel L Penichet; Hannah J Gould; Erika Jensen-Jarolim; Sophia N Karagiannis
Journal:  Cancer Immunol Immunother       Date:  2008-10-22       Impact factor: 6.968

10.  Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform.

Authors:  Josef Singer; Krisztina Manzano-Szalai; Judit Fazekas; Kathrin Thell; Anna Bentley-Lukschal; Caroline Stremnitzer; Franziska Roth-Walter; Margit Weghofer; Mirko Ritter; Kerstin Pino Tossi; Markus Hörer; Uwe Michaelis; Erika Jensen-Jarolim
Journal:  Oncoimmunology       Date:  2016-04-21       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.